FDA Accepts Outlook Therapeutics Appeal for Wet AMD Drug LYTENAVA

The FDA accepted Outlook Therapeutics' formal internal appeal for ONS-5010/LYTENAVA (bevacizumab-vikg), scheduling a meeting with a deciding official in April 2026 to assess whether the agency's December rejection of the drug's biologics license application was warranted.

The mechanism Outlook invoked, a Formal Dispute Resolution Request, is one of the FDA's least-used but most consequential regulatory tools. It allows a company to escalate a disagreement with review division staff directly to a supervisory official, bypassing the standard response cycle. The agency's acceptance of such a request does not indicate it will reverse course; it means only that a senior official has agreed to formally examine whether the scientific and regulatory conclusions in the original decision were sound.

Outlook filed the FDRR after the FDA issued a Complete Response Letter on December 30, 2025, declining to approve LYTENAVA at that stage. A Type A meeting in March 2026, which the FDA convenes only when a program's clinical hold or approval impasse requires urgent resolution, preceded the formal filing. The company's central argument before the deciding official: that clinical data from two pivotal trials, NORSE TWO and NORSE EIGHT, already demonstrate statistically significant and clinically meaningful gains in visual acuity, and that no safety concerns have been raised during the review.

The drug's potential patient population is substantial. Wet AMD, the neovascular form of age-related macular degeneration, affects millions of aging patients and is currently treated with anti-VEGF injections administered directly into the eye. Bevacizumab has been widely used off-label in retinal clinics for years, repackaged by compounding pharmacies into smaller intravitreal doses from oncology-grade stock. The arrangement is cost-effective but carries persistent concerns about sterility variability and traceability.

ONS-5010/LYTENAVA is formulated specifically for ophthalmic use. If approved, it would become the first FDA-sanctioned bevacizumab product designed for the eye, replacing a compounding workaround that lacks standardized labeling and pharmacovigilance infrastructure. Payers and hospital systems that currently procure compounded bevacizumab could find an approved alternative relevant to formulary decisions, particularly if LYTENAVA enters at a price point below existing branded anti-VEGF agents.

Outlook has pointed to approvals in the European Union and the United Kingdom, including commercial launches in Austria and the UK, as evidence that regulators outside the United States have already found the product's data package sufficient. Whether the FDA's deciding official weighs those international approvals as persuasive context remains an open question.

The April meeting will determine one of several outcomes: the deciding official could side with Outlook and direct the review division to approve based on existing data under Approval Pathway 1, require additional analyses or manufacturing commitments, or affirm the original Complete Response Letter. None of those paths is certain, and for retinal specialists managing patients on compounded bevacizumab today, the distance between "accepted for review" and "approved" is the one that matters most.